supplementNot FDA-approvedResearch chemicalAniracetam is not FDA-approved as a drug in the US and is not a standard dietary supplement ingredient; it is sold informally as a nootropicIt has regulatory approval as a prescription drug in some other countries (e.g., historically in parts of Europe and Asia), but that approval status is outside the scope of the cited PubMed sourcesA controlled animal study found no working-memory benefit, underscoring mixed evidence quality
AniracetamBenefits, Dosage & Interactions
Aniracetam is a nootropic compound belonging to the racetam class, first synthesized in the 1970s. It is a fat-soluble compound, which allows it to cross the blood-brain barrier. Research on Aniracetam focuses on cognition and mood. It is typically taken in the morning.
How much Aniracetam do people take?
Older senile-cognitive-disorder trials summarized in the pharmacokinetic review used approximately 1,000–1,500 mg per day of oral aniracetam. Route reported: Oral, in the human trials summarized by the pharmacodynamic/pharmacokinetic review. Frequency reported: Divided into two or three daily doses in the summarized older cognitive-disorder trials. These are amounts documented in the cited studies and labels for Aniracetam — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Insufficient — No primary literature attached to this entry yet.
Evidence strengthInsufficient — nothing graded yet
PreclinicalStrong human evidence
No primary literature attached to this entry yet.
Plasma half-life
Not applicable
Typical timing
in the morning
Food rule
with food
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Older senile-cognitive-disorder trials summarized in the pharmacokinetic review used approximately 1,000–1,500 mg per day of oral aniracetam[1][2]
- Route studied
- Oral, in the human trials summarized by the pharmacodynamic/pharmacokinetic review[1][2]
Reported for Aniracetam in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Aniracetam entry is written from. Each number matches an inline marker above.
- [1]Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveriesNakamura K · CNS Drug Reviews · 2002 · Peer-reviewed · PMID 12070527
- [2]Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disordersLee CR, Benfield P · Drugs & Aging · 1994 · Peer-reviewed · PMID 8199398
- [3]Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's DiseaseLove RWB, Karagiannis TC · Journal of Alzheimer's Disease · 2024 · Peer-reviewed · PMID 38552113
- [4]Aniracetam does not improve working memory in neurologically healthy pigeonsPhillips H, Diekamp B, Fagan A, Wasserman EA · PLoS One · 2019 · Peer-reviewed · PMID 31002681
References & Evidence
Sources on this page that document Aniracetam dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Aniracetam studied for?
What is Aniracetam?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Aniracetam is a nootropic compound belonging to the racetam class, first synthesized in the 1970s. It is a fat-soluble compound, which allows it to cross the blood-brain barrier. In some regions, Aniracetam is available as a dietary supplement, while in others it may be regulated as a prescription drug or not approved for medical use. It is primarily studied for its potential effects on cognitive functions, including memory, learning, and focus, and also for its observed anxiolytic (anxiety-reducing) properties. Unlike some other racetams, Aniracetam is thought to influence both cholinergic and glutamatergic neurotransmission, as well as modulate dopamine and serotonin levels. Its relatively short half-life contributes to its pharmacokinetic profile. (Source: PubChem, DrugBank)
What does the research say about Aniracetam?
Tap a section to expand.
The exact mechanism of action of Aniracetam is not fully understood, but research suggests it involves multiple pathways in the brain. It is believed to act as a positive allosteric modulator of AMPA receptors, a type of glutamate receptor. By enhancing the activity of AMPA receptors, Aniracetam may facilitate faster synaptic transmission and improve neuronal plasticity, which are foundational to learning and memory processes. (Source: DrugBank)
Furthermore, Aniracetam appears to influence the neurotransmitter acetylcholine, though its direct interaction with cholinergic systems may be secondary to its glutamatergic effects. Some studies indicate it may increase acetylcholine release in certain brain regions. (Source: Examine.com)
Beyond these, Aniracetam has been shown to interact with dopamine and serotonin systems. It may modulate the activity of D2 and D3 dopamine receptors and 5-HT2A serotonin receptors, potentially contributing to its observed effects on mood and anxiety. Its fat-solubility means it is rapidly absorbed and can readily cross the blood-brain barrier to exert its effects. (Source: PubChem)
Source for this section: Sources for How does Aniracetam work?: Jumps to this entry in the sources and references list at the end of the page.
Aniracetam has been the subject of research for several potential benefits, primarily in the realm of cognitive function and mood:
* **Cognitive Enhancement:** Studies, particularly in animal models and some human trials, suggest Aniracetam may improve memory formation and recall, learning ability, and overall cognitive processing. These effects are often attributed to its impact on glutamatergic neurotransmission. (Source: Examine.com)
* **Anxiolytic Properties:** A notable aspect of Aniracetam is its potential to reduce anxiety. Research indicates it may have calming effects without significant sedation, possibly due to its modulation of dopamine and serotonin systems. (Source: DrugBank)
* **Mood Modulation:** Some individuals using Aniracetam have reported improvements in mood. This could be related to its anxiolytic properties and its influence on serotonin and dopamine, neurotransmitters widely associated with mood regulation. (Source: anecdotal reports, though scientific literature suggests pathways)
* **Improved Focus and Attention:** By supporting overall cognitive function and potentially reducing anxiety, Aniracetam may indirectly contribute to enhanced focus and attention, allowing for better concentration on tasks. (Source: general research trends in nootropics)
The evidence supporting the benefits of Aniracetam comes from a mix of animal studies, in-vitro research, and some human clinical trials, largely conducted in contexts outside of the United States. For instance:
* **Animal Studies:** A significant portion of research on Aniracetam's cognitive and anxiolytic effects has been conducted in rodents. These studies have frequently demonstrated improvements in memory tasks, learning capabilities, and reductions in anxiety-like behaviors. (Source: numerous peer-reviewed articles, summarized by Examine.com)
* **Human Clinical Trials (European & Asian):** In some countries, Aniracetam has been studied and used to address cognitive decline, particularly in elderly populations or those with certain neurological conditions. These trials have shown some promise in improving symptoms related to cognitive impairment and mood disturbances. However, direct comparisons to regulated pharmaceuticals and large-scale, placebo-controlled trials designed to meet stringent regulatory standards are more limited in English-language literature readily available. (Source: sections of DrugBank describing international use)
* **AMPAR Modulation:** Research consistently points to its interaction with AMPA receptors as a key part of its mechanism, a finding derived from laboratory experiments on neuronal activity. (Source: PubChem)
It is important to note that while initial findings are promising, more extensive, robust, and independent human clinical trials are needed to fully establish the efficacy and safety of Aniracetam for cognitive enhancement and mood regulation in healthy individuals or for specific medical conditions in contexts like the US. Regulatory statuses and medical applications vary significantly by country. (Source: general scientific literature assessment)
Commonly reported side effects of Aniracetam are generally mild and can include:
* Headache, especially when used without a source of choline.
* Nausea or gastrointestinal upset.
* Jitters or anxiety (paradoxical in some individuals).
* Insomnia or difficulty sleeping, particularly if taken too late in the day.
* Fatigue or drowsiness.
Less common side effects might include skin rash or allergic reactions. If any severe or persistent side effects occur, discontinuation and consultation with a healthcare professional are advised.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals with pre-existing medical conditions, particularly those affecting the brain, liver, or kidneys, should exercise caution. Due to limited research on specific populations, pregnant and breastfeeding individuals should avoid Aniracetam. Its effects on blood pressure and heart rate are not extensively studied, so individuals with cardiovascular conditions should be cautious. The long-term safety profile of Aniracetam is not fully established, and potential risks associated with prolonged use are not entirely known.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Aniracetam is generally contraindicated in individuals with known hypersensitivity or allergy to Aniracetam or other racetam derivatives. While specific absolute contraindications derived from large-scale human trials are not exhaustively documented in all public databases (due to its varying regulatory status), caution is advised for individuals with:
* Severe kidney or liver impairment, as these organs are involved in its metabolism and excretion.
* Certain psychiatric disorders, due to its influence on neurotransmitter systems that could potentially exacerbate symptoms.
* History of seizures or epilepsy, as its impact on neuronal excitability requires careful consideration.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Specific drug-drug interaction studies for Aniracetam are limited, but based on its known mechanisms and general pharmacological principles, caution should be exercised when combining it with:
* **Other Nootropics or Cognitive Enhancers:** Combining Aniracetam with other compounds that affect similar neurotransmitter systems (e.g., other racetams, stimulants) could lead to synergistic effects that might be unpredictable or excessive.
* **Anticoagulants/Antiplatelet Drugs:** While not extensively proven, theoretical concerns exist regarding its potential, however small, to affect blood clotting pathways.
* **Psychiatric Medications:** Given Aniracetam's influence on dopamine and serotonin, combining it with antidepressants, anxiolytics, or antipsychotics could alter the effects of these medications or lead to adverse reactions. This interaction is complex and highly individualized.
* **Sedatives or CNS Depressants:** Although Aniracetam is not typically sedating, combining it with CNS depressants could potentially enhance sedative effects.
* **Cholinergic Agents:** Due to its potential to influence acetylcholine, concomitant use with other cholinergic drugs (e.g., donepezil) should be approached with caution to avoid excessive cholinergic activity.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Aniracetam is typically studied as a supplement taken in the morning. Due to its relatively short half-life, which is approximately 1.5 hours, some individuals may choose to divide a daily amount into multiple administrations, though this is not universally practiced. Because Aniracetam is fat-soluble, it is often recommended to take it with food, preferably a meal containing some dietary fat, to enhance absorption. While specific timing within the morning (e.g., before or after breakfast) may vary individually, taking it earlier in the day is generally preferred to avoid potential interference with sleep if any stimulating effects are experienced. (Source: Examine.com)
Source for this section: Sources for When should you take Aniracetam?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Aniracetam is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Aniracetam?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Alpha-GPC | Complementary | Compound pairConfidence: theoretical | Racetam + choline source stack is well-established for cognition and headache prevention.Source pending | Add alpha-GPC 300 mg with each aniracetam dose. |
Frequently asked questions about Aniracetam
Aniracetam is primarily studied for its potential effects on cognitive functions like memory, learning, and focus, and for its anxiolytic (anxiety-reducing) properties. It's often explored as a nootropic compound.
Aniracetam is believed to act as a positive allosteric modulator of AMPA receptors, which are involved in learning and memory. It also influences acetylcholine, dopamine, and serotonin neurotransmitter systems, further contributing to its cognitive and mood-related effects.
Yes, Aniracetam is a fat-soluble compound. This property helps it to be well-absorbed and allows it to effectively cross the blood-brain barrier to exert its effects.
Headaches are a commonly reported side effect, particularly when Aniracetam is used without a sufficient source of choline. Some individuals find that co-supplementation with a choline source can mitigate this side effect.
Due to limited interaction studies, caution is advised. It's especially important to consult a healthcare professional if you are taking other nootropics, psychiatric medications, or any drugs that affect blood clotting, as potential interactions are not well-established. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Aniracetam is a supplement, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Aniracetam is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Aniracetam with no sign-up.
Aniracetam is typically taken in the morning. Published protocols usually have it taken with food. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a supplement like Aniracetam with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Aniracetam: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Aniracetam varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Most protocols have it taken with food. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Aniracetam depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Aniracetam the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Older senile-cognitive-disorder trials summarized in the pharmacokinetic review used approximately 1,000–1,500 mg per day of oral aniracetam. Route reported: Oral, in the human trials summarized by the pharmacodynamic/pharmacokinetic review. Frequency reported: Divided into two or three daily doses in the summarized older cognitive-disorder trials. These are amounts documented in the cited studies and labels for Aniracetam — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Aniracetam?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders(opens PubMed in a new tab)Drugs Aging · 1994 · PMID 8199398 · https://pubmed.ncbi.nlm.nih.gov/8199398/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 2196(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/2196
Verify at
Publisher search links for Aniracetam. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- Mayo Clinic(publisher search, opens in a new tab)Mayo Clinic · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Aniracetam?
Plain-text summary, safe to quote verbatim:
Aniracetam is a nootropic compound belonging to the racetam class, first synthesized in the 1970s. It is a fat-soluble compound, which allows it to cross the blood-brain barrier. Research on Aniracetam focuses on cognition and mood. It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/aniracetam
Aniracetam cheat sheet
DoseRoutine cheat sheet · Supplement
Aniracetam
Aniracetam is a nootropic compound belonging to the racetam class, first synthesized in the 1970s. It is a fat-soluble compound, which allows it to cross the blood-brain barrier.
Evidence
Insufficient
No primary literature attached to this entry yet.
Studied range
Older senile-cognitive-disorder trials summarized in the pharmacokinetic review used approximately 1,000–1,500 mg per day of oral aniracetam
Route
Oral, in the human trials summarized by the pharmacodynamic/pharmacokinetic review
Frequency studied
Divided into two or three daily doses in the summarized older cognitive-disorder trials
Half-life
Reported as short, with rapid hepatic metabolism to active metabolites, per the pharmacokinetic review
Timing
in the morning
With food
with food
Not FDA-approvedResearch chemicalAniracetam is not FDA-approved as a drug in the US and is not a standard dietary supplement ingredient; it is sold informally as a nootropicIt has regulatory approval as a prescription drug in some other countries (e.g., historically in parts of Europe and Asia), but that approval status is outside the scope of the cited PubMed sourcesA controlled animal study found no working-memory benefit, underscoring mixed evidence qualityBrain
Key references
- Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries (2002)
- Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders (1994)
- Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's Disease (2024)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/aniracetam
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Aniracetam — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/aniracetam
What compounds are similar to Aniracetam?
Others in the supplement category or studied for the same goals.
Which goals is Aniracetam used for?
Other compounds studied for the same benefits as Aniracetam.
Continue exploring
See every compound DoseRoutine catalogs for these goals.